Ankur Dhingra is CFO at Summit Therapeutics Inc. (SMMT). They have made 7 open-market trades across 3 companies since 2021, most recently 2026-03-05.
CIK 0001849682
7 open-market purchases totalling $2.3M since 2021, never a sale. Across 7 scored buys the stock is up 34.6% at ninety days, and 31.0 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 71% | 57% | 86% |
| Avg Move | +3.5% | +8.1% | +34.6% |
| Alpha | +4.5% | +8.3% | +31.0% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ILMN | BUY | 2025-05-12 | 2025-05-14 | $81.21 | $991K | +3.1% | +8.6% | +21.7% |
| SMMT | BUY | 2024-03-26 | 2024-03-27 | $3.75 | $375K | -3.1% | -8.3% | +90.3% |
| SMMT | BUY | 2023-12-13 | 2023-12-13 | $2.17 | $44K | +7.0% | +27.6% | +77.4% |
| SMMT | BUY | 2023-03-07 | 2023-03-08 | $1.05 | $412K | +3.8% | -2.5% | +26.1% |
| SMMT | BUY | 2022-08-16 | 2022-08-17 | $0.97 | $35K | +9.7% | +29.9% | +9.7% |
| SMMT | BUY | 2022-08-16 | 2023-03-08 | $0.97 | $13K | +3.8% | -2.5% | +26.1% |
| CDNA | BUY | 2021-11-24 | 2021-11-29 | $42.34 | $423K | +0.0% | +4.0% | -9.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.